Abbott sounds profit warning - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Abbott sounds profit warning

Aug 9, 2000

Abbott Laboratories has sounded a profit warning. “It’s a snake and ladder situation for us” said Mr. Tapan Ray, the Managing Director at the Annual General Meeting of the company held yesterday. The reason off course is due to the impact of the 24.6% price reduction on erythromycin stereate formulations and a 55% reduction on its vitamin formulations ‘Surbex–T’ and ‘Zenbex–T’ imposed in July. These products account for almost 40% of the turnover of the company and the impact is likely to be in the region of almost Rs 100 m in the current financial year.

Even last year the government imposed a price reduction on the products manufactured by the company but there was a corresponding reduction in the prices of the bulk drugs. This year with no such benefits, the cost of production would remain unchanged and the bottomline would take a hit.

Of the multinational pharma companies operating in India, Abbott is one of the few companies with a portfolio extending to hospital products and pediatric nutrition. The parent was voted as among the “50 best companies for minorities” by the Fortune magazine. In India too the company is among the few pharma companies which has not established a 100% subsidiary in India.

Perhaps the only grey area is the lack of liquidity in the stock. With the latest profit warnings from the management, the stock (CMP: Rs 475) is unlikely to fly.

Equitymaster requests your view! Post a comment on "Abbott sounds profit warning". Click here!

  

More Views on News

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

Orchid Pharma Shares Zoom 7,700% in Seven Months. More Gains Ahead? (Views On News)

Jun 3, 2021

Here's why Orchid Pharma shares have rallied 7,700% in seven months.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

Don't Break These 5 Intraday Trading Rules (Fast Profits Daily)

Jun 1, 2021

To become a better intraday trader, follow these rules religiously.

Is the RBI's 'Bubble Talk' Signalling a Market Crash? (Profit Hunter)

May 31, 2021

Is the Indian central bank correct in warning you about a market crash?

Rs 2 Trillion Stimulus Coming to a Stock Market Near You (Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PHARMACIA HEALTH.

  • Track your investment in PHARMACIA HEALTH. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS